ClinicalTrials.gg
CompletedNCT01029340Leopold IUpdated Nov 28, 2016Results posted

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

A Phase 3 interventional study of Recombinant Factor VIII (BAY81-8973) and Recombinant Factor VIII (Kogenate FS, BAY14-2222) in Blood Coagulation Disorders and Hemophilia A, sponsored by Bayer. Completed at 61 sites in 22 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-28.

Primary conditionHemophilia ARegistry: Blood Coagulation DisordersReclassifiedWhy we changed it
Registry
Blood Coagulation Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hemophilia A
Why
  1. The study's listed conditions name Hemophilia A, a narrower term within Blood Coagulation Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
6th of 21
74 · median 50
Started
2009
with 3 others
Phase 3
4 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
3 of 21
Bayer

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 6th largest by enrollment, is one of 4 that started in 2009, is one of 4 in phase 3, and was the 9th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The study will assess the pharmacokinetics (part A) safety, tolerability, and efficacy of prophylaxis treatment (2 to 3 times a week) (part B) with BAY81-8973 over a one year period (split into two six month treatment periods). The study will compare 2 different methods (assays) for measuring the amount of study drug, the chromogenic substrate assay per European Pharmacopeia (CS/EP) with the classical assay (Chromogenic Substrate Adjusted, CS/ADJ). During one six month period patients will receive the study drug where the dose has been measured using the" (CS/EP) and during the other six months period the dose will be measured based on the Chromogenic Substrate Adjusted assay CS/ADJ)

03

Conditions studied

  • Blood Coagulation Disorders
  • Hemophilia A

Browse trials for

Keywords

  • Hemophilia A
  • Factor VIII
  • Prophylaxis
04

In context

Hemophilia A Reclassified

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

This study's enrollment of 74 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.

Browse Hemophilia A studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Hemophilia A, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Blood Coagulation Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 12 to 65 years
  • Severe hemophilia A defined as \< 1% FVIII:C
  • >/= 150 days of previous treatment with FVIII in lifetime
  • Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product
  • No history of or current FVIII inhibitors

Exclusion criteria

Exclusion Criteria:

  • Presence of another bleeding disease that is different from hemophilia A (e.g., von Willebrand disease, hemophilia B)
  • Low count, abnormal kidney function, or liver disease
  • Received treatment with immune suppressing drugs within the last 3 months prior or requires treatment during the study. (Some drugs for , (HIV), and are allowed)
  • Receiving or has received other experimental drugs within 3 months prior to study entry
  • Allergy to Factor VIII or hamsters or mouse protein
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS

    Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between

    Biological: Recombinant Factor VIII (BAY81-8973)

  • Experimental
    Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)

    Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between

    Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

  • Experimental
    Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ

    Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months

    Biological: Recombinant Factor VIII (BAY81-8973)

  • Experimental
    Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP

    Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months

    Biological: Recombinant Factor VIII (BAY81-8973)

  • Experimental
    Arm 5: Recombinant Factor VIII by CS/EP

    Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks

    Biological: Recombinant Factor VIII (BAY81-8973)

Interventions

07

What researchers measure

Primary outcomes

  1. Part A - Area Under the Drug Concentration-time Curve (AUC)

    To examine the Pharmacokinetic (PK) characteristics of BAY 81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.

    Time frame: Samples taken at pre-injection, and at 0.25, 0.5, 1, 3, 6, 8, 24, 30 and 48 hours post injection. AUC calculated from time of injection to infinity.

  2. Part A - Half-life (t 1/2)

    To examine the PK characteristics of BAY81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.

    Time frame: Samples taken at pre-injection, and at 0.25, 0.5, 1, 3, 6, 8, 24, 30 and 48 hours post injection.

  3. Part B - Annualized Number of Total Bleeds

    The annualized number of bleeds experienced by participants

    Time frame: 12 months after randomization

Secondary outcomes

  1. Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII)

    The amount of Factor VIII found in blood samples taken after the injection of the study drug at the beginning of the CS/EP treatment period.

    Time frame: 15-30 minutes after the injection

  2. Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period

    The annualized number of bleeds experienced by participants in each of the two treatment periods

    Time frame: 6 months on each potency

  3. Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed

    The number of injections needed by participants to stop a bleed

    Time frame: 6 months on each potency

  4. Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire

    A measure of how treatment with BAY81-8973 affected the daily life of participants. the scoring system has 100 points. 0 is the worst possible score. 100 is the best possible score. Positive changes from baseline indicate an improvement in quality of life and negative changes indicate a deterioration.

    Time frame: Baseline and 12 months

  5. Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire

    A measure of how treatment with BAY81-8973 affected the daily life of participants. 1.0 = Best possible score, -0.594 = Worst possible score. Positive changes from baseline indicate an improvement and negative changes indicate a deterioration.

    Time frame: Baseline and 12 months

  6. Part A - Number of Participants With Inhibitory Antibody Formation

    A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973

    Time frame: Up to 6 weeks after first injection of study drug

  7. Part B - Number of Participants With Incidence of Inhibitory Antibody Formation

    A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973

    Time frame: Up to 12 months after drug administration

  8. Part C - Number of Participants With Incidence of Inhibitory Antibody Formation

    A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973

    Time frame: before and 3 weeks after surgery

  9. Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)

    A test to analyze the formation of antibodies to HSP-70

    Time frame: Up to 6 weeks after drug administration

  10. Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)

    A test to analyze the formation of antibodies to HSP-70

    Time frame: Up to 12 months after drug administration

  11. Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)

    A test to analyze the formation of antibodies to HSP-70

    Time frame: before and 3 weeks after surgery

  12. Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)

    A test to ensure that participants have not developed antibodies to HCP during the study

    Time frame: Up to 4 weeks after drug administration

  13. Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)

    A test to ensure that participants have not developed antibodies to HCP during the study

    Time frame: Up to 12 months after drug administration

  14. Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)

    A test to ensure that participants have not developed antibodies to HCP during the study

    Time frame: before and 3 weeks after surgery

  15. Part B - Number of Participants With Assessment of the Hemostasis During Major Surgery

    An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations

    Time frame: An average of 1 month after start of treatment

  16. Part C - Number of Participants With Assessment of the Hemostasis During Major Surgery

    An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations

    Time frame: at the time of surgery

08

Results

Posted Nov 18, 2013

Participant flow

Participants were recruited from specialized hemophilia treatment centers.

Part A Treatment Period
Participant flow — Part A Treatment Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started14140000
Participants received treatment14140000
Safety population13140000
Completed14140000
Not completed000000
Part A Follow up Period
Participant flow — Part A Follow up Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started14140000
Completed14140000
Not completed000000
Part B Treatment Period
Participant flow — Part B Treatment Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started00313200
Participants received treatment00303200
Completed00293200
Not completed002000
Withdrew: Withdrawal by subject001000
Withdrew: Protocol violation001000
Part B Follow up Period
Participant flow — Part B Follow up Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started00293200
Completed00293200
Not completed000000
Extension Period
Participant flow — Extension Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started0000055
Completed0000043
Not completed0000012
Withdrew: Adverse event000001
Withdrew: Starting another study000008
Withdrew: Non-compliance000001
Withdrew: Withdrawal by subject000001
Withdrew: Physician decision000001
Part C Treatment Period
Participant flow — Part C Treatment Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started000050
Participants received treatment000050
Completed000050
Not completed000000
Part C Follow up Period
Participant flow — Part C Follow up Period
MilestoneArm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII by CS/EPArm 6: Recombinant Factor VIII (BAY81-8973) Part B + Extension
Started000050
Completed000050
Not completed000000

Outcome measures

PrimaryPart A - Area Under the Drug Concentration-time Curve (AUC)

To examine the Pharmacokinetic (PK) characteristics of BAY 81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.

Time frame:
Samples taken at pre-injection, and at 0.25, 0.5, 1, 3, 6, 8, 24, 30 and 48 hours post injection. AUC calculated from time of injection to infinity.
Reported as:
Geometric mean · Int.units x hours/deciliters (IU*h/dL)
Part A - Area Under the Drug Concentration-time Curve (AUC)
Int.units x hours/deciliters (IU*h/dL)Recombinant Factor VIII (BAY81-8973) - Part AKogenate FS (BAY14-2222) - Part A
Part A - Area Under the Drug Concentration-time Curve (AUC)1889.23 ± 36.111583.91 ± 39.89
PrimaryPart A - Half-life (t 1/2)

To examine the PK characteristics of BAY81-8973 and ensure that the new drug is similar to Kogenate FS. All results are based on the chromogenic assay.

Time frame:
Samples taken at pre-injection, and at 0.25, 0.5, 1, 3, 6, 8, 24, 30 and 48 hours post injection.
Reported as:
Geometric mean · Hours (h)
Part A - Half-life (t 1/2)
Hours (h)Recombinant Factor VIII (BAY81-8973) - Part AKogenate FS (BAY14-2222) - Part A
Part A - Half-life (t 1/2)13.77 ± 28.0012.00 ± 28.20
PrimaryPart B - Annualized Number of Total Bleeds

The annualized number of bleeds experienced by participants

Time frame:
12 months after randomization
Reported as:
Median · Bleeds
Part B - Annualized Number of Total Bleeds
BleedsRecombinant Factor VIII (BAY81-8973) - Part B
Part B - Annualized Number of Total Bleeds1.03 (0.0 to 5.09)
SecondaryPart B - The in Vivo Recovery Values of Human Factor VIII (FVIII)

The amount of Factor VIII found in blood samples taken after the injection of the study drug at the beginning of the CS/EP treatment period.

Time frame:
15-30 minutes after the injection
Reported as:
Median · Kg/dL
Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII)
Kg/dLRecombinant Factor VIII (BAY81-8973) by CS/EP - Part B
Part B - The in Vivo Recovery Values of Human Factor VIII (FVIII)2.50 (2.09 to 2.77)
SecondaryPart B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period

The annualized number of bleeds experienced by participants in each of the two treatment periods

Time frame:
6 months on each potency
Reported as:
Median · Bleeds
Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period
BleedsRecombinant Factor VIII (BAY81-8973) by CS/EP - Part BRecombinant Factor VIII (BAY81-8973) by CS/ADJ - Part B
Part B - Annualized Number of Bleeds in Each 6-month Potency Assignment Period1.9 (0.0 to 4.4)1.9 (0.0 to 7.3)
SecondaryPart B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed

The number of injections needed by participants to stop a bleed

Time frame:
6 months on each potency
Reported as:
Median · Injections
Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed
InjectionsRecombinant Factor VIII (BAY81-8973) by CS/EP - Part BRecombinant Factor VIII (BAY81-8973) by CS/ADJ - Part B
Part B - Control of Bleeding as Measured by the Number of Injections Required to Treat a Bleed1.0 (0 to 11)1.0 (1 to 48)
SecondaryPart B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire

A measure of how treatment with BAY81-8973 affected the daily life of participants. the scoring system has 100 points. 0 is the worst possible score. 100 is the best possible score. Positive changes from baseline indicate an improvement in quality of life and negative changes indicate a deterioration.

Time frame:
Baseline and 12 months
Reported as:
Median · Scores on a scale
Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire
Scores on a scaleRecombinant Factor VIII (BAY81-8973) - Part B
Part B - Changes From Baseline at 12 Months in Quality of Life (QoL) as Measured by Transformed Total Score of Haemo-QoL Questionnaire2.02 (-22.9 to 26.5)
SecondaryPart B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire

A measure of how treatment with BAY81-8973 affected the daily life of participants. 1.0 = Best possible score, -0.594 = Worst possible score. Positive changes from baseline indicate an improvement and negative changes indicate a deterioration.

Time frame:
Baseline and 12 months
Reported as:
Median · Scores on a scale
Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire
Scores on a scaleRecombinant Factor VIII (BAY81-8973) - Part B
Part B - Changes From Baseline at 12 Months in Utility Index as Measured by EQ-5D Questionaire0.00 (-0.6 to 0.5)
SecondaryPart A - Number of Participants With Inhibitory Antibody Formation

A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973

Time frame:
Up to 6 weeks after first injection of study drug
Reported as:
Number · Participants
Part A - Number of Participants With Inhibitory Antibody Formation
ParticipantsRecombinant Factor VIII (BAY81-8973) and Kogenate FS - Part A
Part A - Number of Participants With Inhibitory Antibody Formation0
SecondaryPart B - Number of Participants With Incidence of Inhibitory Antibody Formation

A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973

Time frame:
Up to 12 months after drug administration
Reported as:
Number · Participants
Part B - Number of Participants With Incidence of Inhibitory Antibody Formation
ParticipantsRecombinant Factor VIII (BAY81-8973) - Part B
Part B - Number of Participants With Incidence of Inhibitory Antibody Formation0
SecondaryPart C - Number of Participants With Incidence of Inhibitory Antibody Formation

A test to ensure that participants have not developed antibodies that will interfere with the action of BAY81-8973

Time frame:
before and 3 weeks after surgery
Reported as:
Number · Participants
Part C - Number of Participants With Incidence of Inhibitory Antibody Formation
ParticipantsRecombinant Factor VIII (BAY81-8973) by CS/EP - Part C
Part C - Number of Participants With Incidence of Inhibitory Antibody Formation0
SecondaryPart A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)

A test to analyze the formation of antibodies to HSP-70

Time frame:
Up to 6 weeks after drug administration
Reported as:
Number · Participants
Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)
ParticipantsRecombinant Factor VIII (BAY81-8973) and Kogenate FS - Part A
Part A - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)0
SecondaryPart B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)

A test to analyze the formation of antibodies to HSP-70

Time frame:
Up to 12 months after drug administration
Reported as:
Number · Participants
Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)
ParticipantsRecombinant Factor VIII (BAY81-8973) - Part B
Part B - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)1
SecondaryPart C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)

A test to analyze the formation of antibodies to HSP-70

Time frame:
before and 3 weeks after surgery
Reported as:
Number · Participants
Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)
ParticipantsRecombinant Factor VIII (BAY81-8973) by CS/EP - Part C
Part C - Number of Participants With Incidence of Antibody Formation to Heat-shock Protein (HSP-70)0
SecondaryPart A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)

A test to ensure that participants have not developed antibodies to HCP during the study

Time frame:
Up to 4 weeks after drug administration
Reported as:
Number · Participants
Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)
ParticipantsRecombinant Factor VIII (BAY81-8973) and Kogenate FS - Part A
Part A - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)0
SecondaryPart B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)

A test to ensure that participants have not developed antibodies to HCP during the study

Time frame:
Up to 12 months after drug administration
Reported as:
Number · Participants
Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)
ParticipantsRecombinant Factor VIII (BAY81-8973) - Part B
Part B - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)0
SecondaryPart C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)

A test to ensure that participants have not developed antibodies to HCP during the study

Time frame:
before and 3 weeks after surgery
Reported as:
Number · Participants
Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)
ParticipantsRecombinant Factor VIII (BAY81-8973) by CS/EP - Part C
Part C - Number of Participants With Incidence of Antibody Formation to Host Cell Proteins (HCP)0
SecondaryPart B - Number of Participants With Assessment of the Hemostasis During Major Surgery

An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations

Time frame:
An average of 1 month after start of treatment
Reported as:
Number · Participants
Part B - Number of Participants With Assessment of the Hemostasis During Major Surgery
ParticipantsRecombinant Factor VIII (BAY81-8973) - Part B
Excellent1
Good4
Moderate0
Poor0
SecondaryPart C - Number of Participants With Assessment of the Hemostasis During Major Surgery

An assessment made by surgeons of how effective BAY81-8973 was in stopping bleeding during major operations

Time frame:
at the time of surgery
Reported as:
Number · Participants
Part C - Number of Participants With Assessment of the Hemostasis During Major Surgery
ParticipantsRecombinant Factor VIII (BAY81-8973) by CS/EP - Part C
Excellent1
Good4
Moderate0
Poor0

Adverse events

Collected over From the date of signing informed consent through study completion, i.e. 21 Dec 2009 to 14 Mar 2013. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Recombinant Factor VIII (BAY81-8973) - Part A—0/27 (0%)0/27 (0%)
Kogenate FS (BAY14-2222) - Part A—0/28 (0%)1/28 (3.6%)
Recombinant Factor VIII (BAY81-8973) Part B and Extension—12/62 (19.4%)43/62 (69.4%)
Recombinant Factor VIII (BAY81-8973) by CS/EP - Part C—1/7 (14.3%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRecombinant Factor VIII (BAY81-8973) - Part AKogenate FS (BAY14-2222) - Part ARecombinant Factor VIII (BAY81-8973) Part B and ExtensionRecombinant Factor VIII (BAY81-8973) by CS/EP - Part C
AscitesGastrointestinal disorders0/270/280/621/7
Chest painGeneral disorders0/270/282/620/7
Acute myocardial infarctionCardiac disorders0/270/281/620/7
Spinal painGeneral disorders0/270/281/620/7
ErysipelasInfections and infestations0/270/281/620/7
InjuryInjury, poisoning and procedural complications0/270/281/620/7
ArthralgiaMusculoskeletal and connective tissue disorders0/270/281/620/7
Compartment syndromeMusculoskeletal and connective tissue disorders0/270/281/620/7
Joint range of motion decreasedMusculoskeletal and connective tissue disorders0/270/281/620/7
EpilepsyNervous system disorders0/270/281/620/7
Most frequent other events
Showing 10 of 22
Most frequent other events
EventRecombinant Factor VIII (BAY81-8973) - Part AKogenate FS (BAY14-2222) - Part ARecombinant Factor VIII (BAY81-8973) Part B and ExtensionRecombinant Factor VIII (BAY81-8973) by CS/EP - Part C
DiarrhoeaGastrointestinal disorders0/270/284/622/7
PyrexiaGeneral disorders0/270/281/622/7
NasopharyngitisInfections and infestations0/270/2814/620/7
AnaemiaBlood and lymphatic system disorders0/270/280/621/7
Thymus disorderBlood and lymphatic system disorders0/270/280/621/7
DyspepsiaGastrointestinal disorders0/270/281/621/7
NauseaGastrointestinal disorders0/270/284/621/7
Device related infectionInfections and infestations0/270/280/621/7
AnuriaRenal and urinary disorders0/270/280/621/7
Pleural effusionRespiratory, thoracic and mediastinal disorders0/270/280/621/7

Baseline characteristics

Age, Customized
Age, Customized(Participants)Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII (BAY81-8973) by CS/EP - Part CTotal
Part A < 18 years14NANANANA
Part A =/> 18 years129NANANANA
Part B < 18 yearsNANA55NANA
Part B =/> 18 yearsNANA2527NANA
Part C < 18 yearsNANANANA0NA
Part C =/> 18 yearsNANANANA5NA
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII (BAY81-8973) by CS/EP - Part CTotal
Part A - Female00NANANANA
Part A - Male1313NANANANA
Part B - FemaleNANA00NANA
Part B - MaleNANA3032NANA
Part C - FemaleNANANANA0NA
Part C - MaleNANANANA5NA
Most recent treatment before enrolment in the study
Most recent treatment before enrolment in the study(Participants)Arm 1: Recombinant Factor VIII (BAY81-8973) Then Kogenate FSArm 2: Kogenate FS Then Recombinant Factor VIII (BAY81-8973)Arm 3: Recombinant Factor VIII by CS/EP Then by CS/ADJArm 4: Recombinant Factor VIII by CS/ADJ Then by CS/EPArm 5: Recombinant Factor VIII (BAY81-8973) by CS/EP - Part CTotal
On-demand4348NANA
Prophylaxis10112624NANA
09

Study locations

61 sites
  • Orange, California 92868, United States
  • Sacramento, California 95817, United States
  • Tampa, Florida 33607, United States
  • Boston, Massachusetts 02115, United States
  • East Lansing, Michigan 48823, United States
  • Kansas City, Missouri 64108-9898, United States
  • Cleveland, Ohio 44106-2602, United States
  • Bahia Blanca, Buenos Aires B8001HXM, Argentina
  • Rosario, Santa Fe S2000CKF, Argentina
  • Graz, 8036, Austria
  • Wien, 1090, Austria
  • Zagreb, 10000, Croatia
  • DK-Aarhus N, 8200, Denmark
  • Frankfurt, Hessen 60596, Germany
  • Bonn, Nordrhein-Westfalen 53127, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Homburg, Saarland 66421, Germany
  • Magdeburg, Sachsen-Anhalt 39112, Germany
  • Hongkong, Hong Kong
  • Bangalore, 34, India
  • Mumbai, 400012, India
  • Pune, 411005, India
  • Jakarta, 10430, Indonesia
  • Ramat Gan, 5262000, Israel
  • Catanzaro, Calabria 88100, Italy
  • Napoli, Campania 80131, Italy
  • Napoli, Campania 80144, Italy
  • Roma, Lazio 00168, Italy
  • Milano, Lombardia 20122, Italy
  • Vicenza, Veneto 36100, Italy
  • Oslo, 0027, Norway
  • Karachi, 75300, Pakistan
  • Krakow, 31-501, Poland
  • Warszawa, 02-776, Poland
  • Belgrade, 11000, Serbia
  • Beograd, 11000, Serbia
  • Nis, 18000, Serbia
  • Novi Sad, 21000, Serbia
  • Pretoria, Gauteng 0001, South Africa
  • Parktown, 2132, South Africa
  • Oviedo, Asturias 33006, Spain
  • Santander, Cantabria 39008, Spain
  • A Coruña, 15006, Spain
  • Barcelona, 08035, Spain
  • Jaén, 23007, Spain
  • Valencia, 46026, Spain
  • Göteborg, 413 45, Sweden
  • Malmö, 205 02, Sweden
  • Karolinska Universitetssjukhuset i Solna
    Stockholm, 171 76, Sweden
  • Changhua, 500, Taiwan
  • Taipei, 10016, Taiwan
  • Taipei, 11217, Taiwan
  • Bangkok, 10330, Thailand
  • Bangkok, 10400, Thailand
  • Adana, 01330, Turkey
  • Antalya, 07059, Turkey
  • Izmir, 35-100, Turkey
  • Dundee, Dundee City DD1 9SY, United Kingdom
  • Oxford, Oxfordshire OX3 7LJ, United Kingdom
  • Sheffield, South Yorkshire S10 2JF, United Kingdom
  • London, SE1 7EH, United Kingdom
10

References and documents

Publications

  • Kitchen S, Katterle Y, Beckmann H, Maas Enriquez M. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples. J Thromb Haemost. 2016 Jun;14(6):1192-9. doi: 10.1111/jth.13322. Epub 2016 May 3. PubMed 27002680 ↗
  • Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia. 2016 May;22(3):349-53. doi: 10.1111/hae.12839. Epub 2016 Mar 1. PubMed 26931631 ↗
  • Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, Maas Enriquez M. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016 Sep;22(5):706-12. doi: 10.1111/hae.12952. Epub 2016 Jun 24. PubMed 27339736 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jun 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2009
First posted
Dec 9, 2009
Start
Dec 2009
Primary completionActual
Jun 2012
CompletionActual
Mar 2013
Results first posted
Nov 18, 2013
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01029340
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 9, 2009
Start date
Dec 2009
Primary completion
Jun 2012
Completion
Mar 2013
Results posted
Nov 18, 2013
Last update
Nov 28, 2016

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion